Ligosan

Doxycycline hyclate, the active ingredient in Ligosan, is a tetracycline presented as a tablet for periodontal use. It is employed to manage periodontal disease in adult patients, targeting the bacterial infection that underlies gum inflammation and tissue destruction.

GNH USA supplies Ligosan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution across multiple regions. Customers benefit from reliable supply chains and responsive technical assistance.

Ligosan (doxycycline hyclate) is an antibacterial agent used in the management of periodontal disease.

- Periodontal disease: reduces bacterial load and inflammation in gum tissues. - Acne vulgaris: decreases inflammatory lesions by inhibiting Cutibacterium acnes. - Chlamydial infection: eradicates Chlamydia trachomatis in uncomplicated genital infections.

Adverse reactions may occur with doxycycline therapy and vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, occasionally watery. - Photosensitivity: increased skin sensitivity to sunlight. - Vomiting: occasional emesis after dosing. - Abdominal pain: cramping or discomfort. - Esophagitis: irritation of the esophageal lining.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis, urticaria, or angioedema. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction. - Hepatotoxicity: liver enzyme elevation or hepatitis. - Intracranial hypertension: headache, visual disturbances. - Clostridioides difficile infection: severe colitis. - Hematologic abnormalities: thrombocytopenia or neutropenia.

Before prescribing Ligosan, clinicians should consider several safety aspects.

- Pregnancy: category D; use only if benefits outweigh potential fetal risks. - Breastfeeding: doxycycline is excreted in milk; assess infant risk before continuation. - Renal impairment: dose adjustment may be required in patients with reduced clearance. - Photosensitivity: advise patients to avoid prolonged sun exposure and use protective clothing. - Drug interactions: review concomitant medications for potential alterations in efficacy or toxicity. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Doxycycline may interact with several medicines, necessitating careful management.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce doxycycline absorption. - Warfarin: may potentiate anticoagulant effect, increasing bleeding risk. - Oral retinoids: combined use raises risk of intracranial hypertension.

Moderate Interactions (Monitor Closely): - Oral contraceptives: doxycycline can diminish hormonal efficacy, consider backup contraception. - Cyclosporine: may increase doxycycline plasma concentrations. - Barbiturates: can lower doxycycline levels, potentially reducing therapeutic effect.